Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Beyond The United States into the Eastern Mediterranean region. Israel and Turkey are geographies with a high prevalence of individuals with CF class one or null mutations, which will meaningfully support our recruitment efforts and efficiencies for this study. Unlike The United States, the The United United States, in our ARCT032 study from Turkey and Israel, respectively. Clinical execution remains on schedule, and we are laser focused on generating the data needed to support the phase three decision expected in Q4 twenty twenty six. Turning to our OTC deficiency program, ARCT-eight 10. During the quarter, we completed enrollment of the ongoing phase two study, and all enrolled subjects completed study drug dosing. This is an important operational milestone and allows us to now focus on evaluating the supplementary data generated from the enrolled study population. We remain grateful for the continuing support, ongoing encouragement, and strong engagement on behalf of our ARCT-eight 10 OTC deficiency study by the patients, their families, and the rare disease care community. Thank you for all your collective help and interest in our development program. Our current efforts are focused on data review, preparation for upcoming regulatory interactions, and planning for an end of phase two meeting regarding the path forward across both adult and pediatric development. We expect to communicate both the data and regulatory plan for OTC deficiency program in Q3 twenty twenty six. Across both our rare disease programs, our focus remains on disciplined clinical execution, high quality data generation, and productive regulatory engagement to support efficient development decisions. With that, I will turn the call over to Dennis. Thanks, Alan, and good afternoon, everyone. Ou...